» Articles » PMID: 34581247

Cross-sectional Study on the Impact of Age, Menopause and Quality of Life on Female Sexual Function

Overview
Publisher Informa Healthcare
Date 2021 Sep 28
PMID 34581247
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

We sought to determine the prevalence of female sexual dysfunction (FSD) and to examine the influence of age, menopausal state and quality of life (QoL) on the female sexual function (FSF) of healthy women and those with benign gynaecological disease. With this purpose, we conducted a cross-sectional study, based on self-report questionnaires (sociodemographic, WHOQOL-BREF and FSFI), enrolling 107 women. Some 51.6% ( = 55) were diagnosed with FSD. We found no statistical significant differences between grouped reason for consultation and FSFI total score ( = .72) and its domains ( > .05). The results showed a negative strong correlation between age and FSFI total score (S= -0.71) and a positive moderate correlation between WHOQOL-BREF and FSFI total scores (S = 0.39). We observed statistically significant differences between menopausal state and FSFI total score ( = .001). In conclusion, the prevalence of FSD in our population was 51.6%. Our study results reveal that a reduction in FSFI scores has a negative impact on QoL and vice versa, regardless of the reason for consultation. Elderly age and postmenopausal state have deleterious effects on FSF.Impact statement Poor QoL can adversely affect FSF and vice versa. The study of FSF is relatively recent and there is controversy regarding the deleterious effects of elderly age and menopause on FSF. The prevalence of FSD is difficult to precisely determine, given the studies' use of different definitions for FSD and the highly heterogeneous study populations, as well as the types of tests and questionnaires employed. Sexual difficulties are problems seldom discussed between patients and their physicians. Lack of time, misconceptions, shame and frustration, considering sexuality as too intimate to discuss in the doctor's office, uncertainty regarding therapeutic options and insufficient training of health professionals are just some of the reasons mentioned for not addressing sexual dysfunction in a general consultation. Our study is the first research in Spain on the impact of age, menopause and QoL on gynaecological patients´ FSF. Our results indicate that an impaired FSF could be related to poorer well-being and QoL; however, benign gynaecological disease does not appear to affect FSF. Elderly age and postmenopausal state can have deleterious effects on FSF. Sexuality is an important aspect of QoL. Therefore, gynaecologists should discuss issues of sexuality with their patients in routine visits, especially in case of elderly and postmenopausal women. In addition, gynaecologists should train in the diagnosis and treatment of the female sexual dysfunction.

Citing Articles

Qualitative study exploring the experiences of sexual dysfunction in premenopausal women with type 1 diabetes.

Hashim R, Forde R, Parsons J, Ausili D, Forbes A Diabet Med. 2024; 42(1):e15439.

PMID: 39302078 PMC: 11635588. DOI: 10.1111/dme.15439.


Sexual Activity, Function, and Satisfaction in Reproductive-Aged Females Living with Chronic Kidney Disease.

Corbett K, Chang D, Riehl-Tonn V, Ahmed S, Rao N, Kamar F Healthcare (Basel). 2024; 12(17).

PMID: 39273752 PMC: 11395406. DOI: 10.3390/healthcare12171728.


The Effect of Body Practices and Physical Exercise on Sexual Function of Menopausal Women. A Systematic Review with Meta-Analysis.

Fausto D, Bocchi Martins J, Moratelli J, Garcia Lima A, de Azevedo Guimaraes A Int J Sex Health. 2024; 35(3):414-426.

PMID: 38601725 PMC: 10903687. DOI: 10.1080/19317611.2023.2220327.


Sexuality in Postmenopausal Women with Genital Prolapse.

Fernandez Risquez A, Carballo Garcia A, Hijona Elosegui J, Mendoza Ladron de Guevara N, Presa Lorite J J Clin Med. 2023; 12(19).

PMID: 37834934 PMC: 10573593. DOI: 10.3390/jcm12196290.


The effect of conjugated estrogens vaginal cream and a combined vaginal cream of vitamins D and E in the treatment of genitourinary syndrome.

Radnia N, Hosseini S, Vafaei S, Pirdehghan A, Mehrabadi N J Family Med Prim Care. 2023; 12(3):507-516.

PMID: 37122641 PMC: 10131947. DOI: 10.4103/jfmpc.jfmpc_1364_22.